Clinical predictors of Pseudomonas aeruginosa bacteremia among Gram-negative bacterial infections in non-neutropenic patients with solid tumor

Journal of Infection

Volumn 63, Issue 3, 2011, Pages 207-214

  Joo, Eun Jeong ^a   Kang, Cheol In ^a   Ha, Young Eun ^a   Kim, Jungok ^a   Kang, Seung Ji ^a   Park, So Yeon ^a   Lee, Nam Yong ^a   Wi, Yu Mi ^a   Chung, Doo Ryeon ^a   Peck, Kyong Ran ^a   Song, Jae Hoon ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Bacteremia; Cancer; Non neutropenia; Predictor; Pseudomonas aeruginosa

Indexed keywords

CEPHALOSPORIN;

ABDOMINAL INFECTION; ADULT; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL PNEUMONIA; BILIARY TRACT CANCER; BLADDER CANCER; CANCER MORTALITY; CITROBACTER; CLINICAL EVALUATION; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENTEROBACTER; ENTEROBACTERIACEAE INFECTION; ENVIRONMENTAL EXPOSURE; ESCHERICHIA COLI; FEMALE; HOSPITAL INFECTION; HUMAN; INDWELLING CATHETER; INVASIVE PROCEDURE; KLEBSIELLA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PREDICTION; PSEUDOMONAS INFECTION; RISK FACTOR; SEPTIC SHOCK; SOLID TUMOR; STOMACH CANCER; TREATMENT OUTCOME;

AGED; ANTI-INFECTIVE AGENTS; BACTEREMIA; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RISK FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 80052272302     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2011.06.011     Document Type: Article

References (26)

1. Kang C.I., Kim S.H., Park W.B., Lee K.D., Kim H.B., Kim E.C., et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005, 49:760-766.
2. Raymond D.P., Pelletier S.J., Crabtree T.D., Evans H.L., Pruett T.L., Sawyer R.G. Impact of antibiotic-resistant Gram-negative bacilli infections on outcome in hospitalized patients. Crit Care Med 2003, 31:1035-1041.
3. Schechner V., Nobre V., Kaye K.S., Leshno M., Giladi M., Rohner P., et al. Gram-negative bacteremia upon hospital admission: when should Pseudomonas aeruginosa be suspected?. Clin Infect Dis 2009, 48:580-586.
4. Hughes W.T., Armstrong D., Bodey G.P., Bow E.J., Brown A.E., Calandra T., et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002, 34:730-751.
5. Joo E.J., Kang C.I., Ha Y.E., Kang S.J., Park S.Y., Chung D.R., et al. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome. Microb Drug Resist 2011, 17:305-312.
6. Aloush V., Navon-Venezia S., Seigman-Igra Y., Cabili S., Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 2006, 50:43-48.
7. Falagas M.E., Karageorgopoulos D.E. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis 2008, 46:1121-1122. author reply 2.
8. Kang C.I., Kim S.H., Park W.B., Lee K.D., Kim H.B., Kim E.C., et al. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microb Drug Resist 2005, 11:68-74.
9. Joo EJ, Kang CI, Ha YE, Park SY, Kang SJ, Wi YM, et al. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection. Infection, in press.
10. Kim S.H., Park W.B., Lee K.D., Kang C.I., Kim H.B., Oh M.D., et al. Outcome of Staphylococcus aureus bacteremia in patients with eradicable foci versus noneradicable foci. Clin Infect Dis 2003, 37:794-799.
11. McDonald J.R., Friedman N.D., Stout J.E., Sexton D.J., Kaye K.S. Risk factors for ineffective therapy in patients with bloodstream infection. Arch Intern Med 2005, 165:308-313.
12. Friedman N.D., Kaye K.S., Stout J.E., McGarry S.A., Trivette S.L., Briggs J.P., et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002, 137:791-797.
13. Performance standards for antimicrobial susceptibility testing; Nineteenth Informational Supplement 2009, Clin Lab Stand Insitutue, M100-S19.
14. Cheong H.S., Kang C.I., Wi Y.M., Kim E.S., Lee J.S., Ko K.S., et al. Clinical significance and predictors of community-onset Pseudomonas aeruginosa bacteremia. Am J Med 2008, 121:709-714.
15. Kang C.I., Kim S.H., Bang J.W., Kim H.B., Kim N.J., Kim E.C., et al. Clinical identifiers and pathogenic significance of Pseudomonas aeruginosa bacteremia, in comparison with Klebsiella pneumoniae and Enterobacter species. Infect Chemother 2006, 38:61-69.
16. Laupland K.B., Parkins M.D., Church D.L., Gregson D.B., Louie T.J., Conly J.M., et al. Population-based epidemiological study of infections caused by carbapenem-resistant Pseudomonas aeruginosa in the Calgary Health Region: importance of metallo-beta-lactamase (MBL)-producing strains. J Infect Dis 2005, 192:1606-1612.
17. Lai H.P., Hsueh P.R., Chen Y.C., Lee P.I., Lu C.Y., Lu M.Y., et al. Bacteremia in hematological and oncological children with febrile neutropenia: experience in a tertiary medical center in Taiwan. J Microbiol Immunol Infect 2003, 36:197-202.
18. Chatzinikolaou I., Abi-Said D., Bodey G.P., Rolston K.V., Tarrand J.J., Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med 2000, 160:501-509.
19. Berghmans T., Sculier J.P., Klastersky J. A prospective study of infections in lung cancer patients admitted to the hospital. Chest 2003, 124:114-120.
20. Thuong M., Arvaniti K., Ruimy R., de la Salmoniere P., Scanvic-Hameg A., Lucet J.C., et al. Epidemiology of Pseudomonas aeruginosa and risk factors for carriage acquisition in an intensive care unit. J Hosp Infect 2003, 53:274-282.
21. Horasan E.S., Ersoz G., Horoz M., Goksu M., Karacorlu S., Kaya A. Risk factors for infections caused by multidrug-resistant bacteria in patients with solid tumours. Scand J Infect Dis 2011, 43:107-111.
22. Cheong H.S., Kang C.I., Wi Y.M., Ko K.S., Chung D.R., Lee N.Y., et al. Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with community-onset Pseudomonas aeruginosa bacteraemia. Eur J Clin Microbiol Infect Dis 2008, 27:1219-1225.
23. Lodise T.P., Patel N., Kwa A., Graves J., Furuno J.P., Graffunder E., et al. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 2007, 51:3510-3515.
24. Kang C.I., Kim S.H., Kim H.B., Park S.W., Choe Y.J., Oh M.D., et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003, 37:745-751.
25. Blot S., Vandewoude K., De Bacquer D., Colardyn F. Nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in critically ill patients: clinical outcome and length of hospitalization. Clin Infect Dis 2002, 34:1600-1606.
26. Yuen M.F., Hou J.L., Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 2009, 24:346-353.